Biovail

The optics may be terrible in these tough times, but flying the company plane isn’t always the evil it’s made out to be

You have to feel for the shareholders of Biovail. Today at the drug company’s annual general meeting in Toronto investors were forced to choose between two difficult options—the pain of uncertainty, or the certainty of pain. They went with the former.